Navigation Links
Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
Date:7/21/2009

CHICAGO, July 21 /PRNewswire-FirstCall/ -- Today at the American Association for Clinical Chemistry's Clinical Lab Expo in Chicago, Abbott (NYSE: ABT) announced the launch of a new diagnostic instrument -- the ARCHITECT(R) c4000(R) clinical chemistry analyzer which performs diagnostic tests that monitor general health including a patient's levels of sodium, potassium, chloride and organ function.

The new ARCHITECT c4000 seamlessly integrates with Abbott's i1000SR immunoassay analyzer to form the ARCHITECT ci4100(TM), an automated analyzer that completes both immunoassay and chemistry tests on one platform. With these two products, Abbott now offers chemistry, immunoassay, and integrated diagnostic testing solutions to improve the performance and efficiency of laboratories of all sizes.

Abbott is the only company offering high, medium and low-volume integrated diagnostic testing solutions that leverage the same software, reagents and sample carriers. Standardizing to a single family of instruments like Abbott's ARCHITECT products gives labs the ability to optimize processes, minimize errors, and reduce result variability, which is becoming increasingly important as clinicians rely more and more on laboratory diagnostics to guide their treatment decisions.

Abbott's family of ARCHITECT instruments generates accurate and equivalent results across instruments and labs, even at multiple sites, because these instruments share detection technologies, reagents, and software. This standardization is critical as hospitals and the Obama administration continue to emphasize the importance of capturing patient histories in electronic medical records. In a recent study of U.S. hospitals, 73 percent of health care decision makers and executives identified electronic medical records (E
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Tara Haelle HealthDay ... -- Measuring how quickly a child,s brain processes sounds ... a new study. Observing children,s brainwaves may ... possible, the study authors reported. "The finding that ... associated with autism severity is hugely promising," said senior ...
(Date:9/22/2014)... “The Race is On!” for the 22nd Susan G. ... 2014 as it moves to its new location at Cesar ... fundraising and awareness event for Susan G. Komen® Central and ... the Cure provides supporters of all ages an opportunity to ... in. , “Moving the Race to Cesar Chavez Plaza ...
(Date:9/22/2014)... Mich. Many parents whose kids participate in athletics ... education, but that,s not enough to ensure parents are ... University of Michigan C.S. Mott Children,s Hospital National Poll ... of the 912 parents of middle and high school ... education: , , 23% have read a brochure ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
(Date:9/22/2014)... to laser weapons, the Office of Naval Research (ONR) ... Modern Day Marine exposition that will prepare Marines as ... , ONR program officers will be in Booth No. ... Corps Base Quantico, to discuss how their research contributes ... "fast, austere and lethal." , ONR,s Expeditionary Maneuver Warfare ...
Breaking Medicine News(10 mins):Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Some concussion education more useful than others, parents say 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3Health News:Modern Day Marine: ONR features technology for marines of the future 2
... causes epileptic seizures, but researchers from Melbournes Howard Florey ... with the help of their newly developed genetically modified ... mutation based mouse model in the world that mimics ... Dr Steven Petrou and his team to understand the ...
... the University of Pennsylvania School of Medicine have found ... the prognosis of patients with head and neck cancers. ... of CANCER. , The belief that a patients psychological ... cancer is one that has been prominent among patients ...
... upbeat, less positive patients , , MONDAY, Oct. 22 (HealthDay ... how long a person with cancer will survive, a ... that among head and neck cancer patients, emotional health ... factor affecting prognosis. , "We anticipated finding that emotional ...
... Sold Exclusively by GE Healthcare Expands Company ... Offerings within Worldwide Hospital Market, ... CSCX ), a global leader in advanced cardiac monitoring,and ... and has begun full shipments of its new "crash ...
... a prescription NSAID (non-steroidal anti- inflammatory drug) treatment that can be applied directly to ... osteoarthritis pain ... in both the knees and the joints ... of the hands * Offers highly effective ...
... and Item finalize settlement agreement with Teva, ... 22 Astellas,Pharma Inc. ("Astellas"; headquarters: Tokyo; ... ("King"; NYSE: KG) and Teva,Pharmaceutical Industries Ltd. ... of Astellas, along with Item Development AB ...
Cached Medicine News:Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 2Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Adenoscan(R) Patent Lawsuits Settled 2Health News:Adenoscan(R) Patent Lawsuits Settled 3Health News:Adenoscan(R) Patent Lawsuits Settled 4
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
(Date:9/22/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a ... announced that study designs and progress from two of ... global Phase 3 clinical trial in relapsed/refractory soft tissue ... in small cell lung cancer, will be presented at ... being held September 26-30, in Madrid, Spain ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
Medicine Products: